Idarucizumab as Antidote to Intracerebral Hemorrhage Underrx
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab.

https://goo.gl/TK1K6J
Dr. A●●●d F●●●●q and 4 others like this
Like
Comment
Share